Business Context and Reporting Period
Company: 22nd Century Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 30, 2021
Principal Office: Buffalo, New York
Trading Symbol: XXII (NYSE American)
This filing reports the entry into a material definitive agreement on April 30, 2021, between 22nd Century Group, Inc. and KeyGene N.V. regarding their collaborative research partnership focused on the Cannabis Sativa L. plant.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual amendment rather than financial performance results.
Material Changes and Agreement Details
The Company entered into a First Amended and Restated Framework Collaborative Research Agreement with KeyGene N.V., modifying the original 2019 agreement. Key modifications include:
- Term Extension: The agreement term is extended by 3 years, now running from first-quarter 2024 to first-quarter 2027. The Company retains an option for an additional 2-year extension through first-quarter 2029.
- Exclusivity and Scope: The agreement preserves exclusivity for KeyGene regarding the Cannabis Sativa L. plant. It adds a framework for a future Master Development Agreement related to other plant varieties.
- Payment Schedule Adjustments:
- Reduction in the Company's required spend on cannabis research for the first quarter of 2021.
- Royalty payments and consulting fees paid to KeyGene can now serve as a credit against the required annual spend to maintain exclusivity.
- Portion of the annual research spend may be shifted to plant research outside the Cannabis field while maintaining exclusivity within the field.
- Governance: Establishment of an Executive Committee with members from both companies to focus on strategic development.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release on May 4, 2021, announcing these strategic modifications. The full terms of the agreement will be filed as an exhibit to the Quarterly Report on Form 10-Q for the second quarter ended June 30, 2021.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard qualification that the summary is subject to the full terms of the agreement.
Investor Verification Checklist
- Verify the full text of the First Amended and Restated Framework Collaborative Research Agreement in the upcoming Form 10-Q filing.
- Confirm the specific dollar amount of the reduced required spend for the first quarter of 2021.
- Review the press release dated May 4, 2021 (Exhibit 99.1) for additional strategic context.
- Monitor future filings for the establishment and composition of the new Executive Committee.